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AbstrAct
Objectives Elevated blood cholesterol is a modifiable 
risk factor for cardiovascular disease. Cholesterol level 
surveillance is necessary to study population disease 
burden, consider priorities for prevention and intervention 
and understand the effect of diet, lifestyle and treatment. 
Previous studies show a cholesterol decline in recent 
decades but lack data to follow individuals born in different 
decades throughout life.
Methods We investigated changes in age-specific and 
birth cohort-specific total cholesterol (TC) levels in 43 710 
women and men born in 1905–1977 (aged 20–95 years 
at screening) in the population-based Tromsø Study. Fifty-
nine per cent of the participants had more than one and 
up to six repeated TC measurements during 1979–2016. 
Linear mixed models were used to test for time trends.
results Mean TC decreased during 1979–2016 in both 
women and men and in all age groups. The decrease in TC 
in age group 40–49 years was 1.2 mmol/L in women and 
1.0 mmol/L in men. Both the 80th and the 20th percentile 
of the population TC distribution decreased in both sexes 
and all age groups. Longitudinal analysis showed that TC 
increased with age to a peak around middle age followed 
by a decrease. At any given age, TC significantly decreased 
with increase in year born. Lipid-lowering drug use was 
rare in 1994, increased thereafter, but was low (<3% 
in women and <5% in men) among those younger than 
50 years in all surveys. Between 1994 and 2016, lipid-
lowering drug treatment in individuals 50 years and older 
explained 21% and 28% of the decrease in TC levels in 
women and men, respectively.
conclusions We found a substantial decrease in mean TC 
levels in the general population between 1979 and 2016 in 
all age groups. In birth cohorts, TC increased with age to a 
peak around middle age followed by a decrease.
IntrOductIOn
High blood cholesterol is a modifiable risk 
factor for cardiovascular disease (CVD)1 and 
was estimated to be responsible for more 
than 10% of global CVD deaths in 2010.2 
Reduction in total cholesterol was found to 
account for about one-third of the reduction 
in coronary heart disease (CHD) incidence3 
and mortality4–6 in recent studies. Although 
cholesterol levels decreased in Western 
Europe, North America and Australasia in 
recent decades, cholesterol levels in these 
regions are still well above the recommended 
goal of <5 mmol/L.7 A reversal of decreasing 
cholesterol trends has been reported from 
Sweden and Finland, coinciding with an 
increase in fat intake.8 9 Taken together, 
surveillance of cholesterol trends is needed 
to study disease burden, to consider priori-
ties for CVD prevention and intervention and 
to understand the effect of diet, lifestyle and 
lipid-lowering drug (LLD) use.7
Previous population studies of trends in 
cholesterol levels lack data to follow long-term 
Longitudinal and secular trends in total 
cholesterol levels and impact of lipid-
lowering drug use among Norwegian 
women and men born in 1905–1977 in 
the population-based Tromsø 
Study 1979–2016
Laila Arnesdatter Hopstock,1,2 Kaare Harald Bønaa,1,3,4 Anne Elise Eggen,1 
Sameline Grimsgaard,1 Bjarne K Jacobsen,1 Maja-Lisa Løchen,1,5 
Ellisiv B Mathiesen,6,7 Inger Njølstad,1 Tom Wilsgaard1
To cite: Hopstock LA, Bønaa KH, 
Eggen AE, et al.  Longitudinal 
and secular trends in total 
cholesterol levels and impact 
of lipid-lowering drug use 
among Norwegian women and 
men born in 1905–1977 in 
the population-based Tromsø 
Study 1979–2016. BMJ Open 
2017;7:e015001. doi:10.1136/
bmjopen-2016-015001
 ► Prepublication history and 
additional material for this paper 
are available online. To view 
please visit the journal (http:// 
dx. doi. org/ 10. 1136/ bmjopen- 
2016- 015001).
Received 2 November 2016
Revised 17 July 2017
Accepted 26 July 2017
For numbered affiliations see 
end of article.
correspondence to
Dr Laila Arnesdatter Hopstock;  
 laila. hopstock@ uit. no
Research
strengths and limitations of this study
 ► A strength of this study is the inclusion of repeated 
measurements of total cholesterol and lipid-lowering 
drug use in the same individuals in a population-
based sample, over four decades.
 ► A limitation of this study is that, due to different 
sampling procedures between the surveys, not 
all birth cohorts could be followed from young 
adulthood to older age.
 ► Another limitation is that 41% of the participants 
contributed with only one blood sample.
 ► Further, a limitation is that data on weight, diet and 
other potential mediators of cholesterol changes 
have not been included in the analyses.
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trends combined with information on LLD treatment in 
individuals born in different decades.7 In the present 
analysis from the large population-based Tromsø Study, 
we included 43 710 men and women born between 1905 
and 1977, aged 20–95 years at screening, who participated 
in surveys conducted from 1979 to 2016. The study design 
allowed us to analyse both secular trends of total serum 
cholesterol (ie, cross-sectional trends in age groups) and 
longitudinal trends (ie, follow individuals or birth cohorts 
with repeated measurements) and LLD use in a general 
population.
MethOds
Study population
The Tromsø Study is an ongoing population-based cohort 
study in the municipality of Tromsø, Northern Norway, 
with a population of 75 000 inhabitants (46 000 in 1979). 
The study includes six surveys (Tromsø 1: 1974, Tromsø 2: 
1979–1980, Tromsø 3: 1986–1987, Tromsø 4: 1994–1995, 
Tromsø 5: 2001, Tromsø 6: 2007–2008 and Tromsø 7: 
2015–2016) to which total birth cohorts and representa-
tive samples of the population were invited.10 Response 
rates were between 66% and 79%. A total of 45 473 women 
and men participated.
Participants in at least one of the surveys conducted 
from 1979 to 2016 (Tromsø 2–7, n=44 489) were eligible 
for the present analysis. We excluded the first survey 
(Tromsø 1) because it included men only, subjects who 
did not consent to research (n=181), were born before 
1905 (n=29), attended Tromsø 3 without an invitation or 
were younger than 20 years of age (n=499) or did not 
have any cholesterol measurements (n=70). Altogether, 
we included 43 710 subjects (51% women) aged 20–95 
years. Fifty-nine per cent had more than one measure-
ment (19% had two, 15% had three, 12% had four, 8% 
had five and 5% had six repeated cholesterol measure-
ments).
The Regional Committee of Medical and Health 
Research Ethics and the Norwegian Data Protection 
Authority have approved the Tromsø Study, and therefore 
all procedures performed were in accordance with the 
1964 Declaration of Helsinki and its later amendments. 
The participants have given informed consent.
Measurements
Non-fasting venous blood samples were collected 
by standard methods by trained personnel, with the 
participant sitting. A brief venous stasis applied to the 
upper arm was released before venipuncture. Serum 
total cholesterol concentrations were analysed within 
48 hours by CHOD-PAP enzymatic colorimetric methods 
with commercial kits (Boehringer-Mannheim (Tromsø 
2–4) and Roche Diagnostics (Tromsø 5–7), Mannheim, 
Germany) at the Department of Laboratory Medicine, 
University Hospital of North Norway, Tromsø. Use of 
LLD was assessed through questionnaires (Tromsø 4–7, 
except participants ≥70 years in Tromsø 4) and a written 
list of brand names of medications used on regular 
basis checked by health personnel at the study site (in 
Tromsø 4, only in individuals aged 55–74 years and 5.5% 
of participants >74 years). Thus, 1362 participants 75–97 
years were not asked about LLD use in Tromsø 4. Self-re-
port of medication used regularly for chronic conditions 
is considered accurate.11 A comparison of data from 
Tromsø 6 and information from the Norwegian Prescrip-
tion Database (time window 180 days) showed a kappa 
value of 0.94 (95% CI 0.93 to 0.95) for LLD (A E Eggen, 
unpublished data, 2017).
statistics
Secular
Population means of total cholesterol (mmol/L) 
(table 1) according to survey number were estimated in 
sex-specific analyses and 10-year age groups using linear 
mixed models with indicator variables of survey number 
as independent variables. Linear mixed models were used 
to estimate linear trend over surveys within each 10-year 
age group using date of surveys as a continuous time vari-
able. The unit for the regression coefficient was reported 
per 10 years. In a separate set of analyses, we assessed 
whether the observed trends in total cholesterol were 
independent of high-density lipoprotein (HDL) choles-
terol by including HDL cholesterol as a covariate in the 
models. Linear mixed models were also used to estimate 
secular trends in age-adjusted means across surveys within 
two age intervals, 30–49 years and 50–89 years (figure 1). 
Adjustment for age was performed by modelling cubic 
polynomials for age. An autoregressive order 1 covari-
ance matrix was specified to control for dependencies 
between repeated measures using restricted maximum 
likelihood as the estimation method. Descriptive charac-
teristics were calculated by survey (online supplementary 
material table 1).
We calculated the 20th, 50th and 80th centiles of the 
cholesterol distribution in Tromsø 2–7 for each 10-year 
age group in women and men (online supplementary 
material tables 2 and 3) and the differences in cholesterol 
concentrations between Tromsø 4 and Tromsø 7 in mean 
and 20th, 50th and 80th centiles to track changes in the 
cholesterol distribution (table 2).
The proportion (%) of current users of LLD (table 3) 
was calculated in sex-specific analyses according to strata 
of surveys and 10-year age groups, with generalised estima-
tion equation to test for linear trend over surveys within 
each 10-year age group using date of surveys as a contin-
uous variable. An exchangeable covariance matrix was 
specified to control for dependencies between repeated 
observations.
Time trends in population studies may be related 
to selection bias as healthier subsets of the population 
are likely to participate in later (repeated) surveys. We 
therefore calculated differences in cholesterol levels 
dependent on participation in one or more surveys for 
sensitivity analyses (online supplementary material tables 
4 and 5).
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Figure 1 Trends in age-adjusted mean total cholesterol 
(mmol/L) in women (dotted line) and men (solid line) in 1979–
2008 aged 30–49 years and 50–89 years with 95% CIs. The 
Tromsø Study 1979–2016.
Table 2 Differences in cholesterol levels (mmol/L) between 1994–1995 and 2015–2016 by sex and age group: the Tromsø 
Study
Age group 
(years) Mean SD 20th centile 50th centile 80th centile
Difference between 
80th and 20th centile
Women
  40–49 −0.79 −0.23 −0.62 −0.73 −0.96 −0.34
  50–59 −0.98 −0.27 −0.74 −0.96 −1.19 −0.45
  60–69 −1.27 −0.21 −1.11 −1.22 −1.36 −0.25
  70–79 −1.54 −0.17 −1.45 −1.40 −1.72 −0.27
  80–89 −1.38 −0.17 −1.34 −1.48 −1.52 −0.18
Men
  40–49 −0.74 −0.14 −0.60 −0.68 −0.93 −0.34
  50–59 −0.89 −0.13 −0.80 −0.90 −1.01 −0.21
  60–69 −1.20 −0.09 −1.14 −1.19 −1.26 −0.12
  70–79 −1.45 −0.12 −1.45 −1.38 −1.46 −0.01
  80–89 −1.21 −0.06 −1.19 −1.38 −1.32 −0.13
The change in cholesterol levels that could be explained 
by LLD use was estimated by the expression:
 (βt − β∗t )/βt 
where βs are regression coefficients for the linear time 
trend in cholesterol in linear mixed models adjusted for 
age, βt, and additional adjustment for LLD use, βt*.
We created cholesterol kernel density distribution 
curves12 for Tromsø 4 and Tromsø 7 (figure 2), using the 
kde procedure in SAS . 
Longitudinal
Linear mixed models were used to estimate longitu-
dinal cholesterol means over time according to sex and 
birth cohort. The fixed time variable in the models was 
either survey number (figure 3A,B) or attained age 
(figure 3C,D), with additional analyses for never-users of 
LLD (online supplementary material figure 1). Linear 
mixed models were used to estimate linear trends over 
surveys restricted to the period 1994–2016 using date of 
survey as a continuous time variable. In order to estimate 
different time trends across birth cohorts, we added indi-
cator variables for each 10-year birth cohort and two-way 
interaction terms between each birth cohort and time. 
We also modelled birth cohort as an ordinal variable in 
separate models. Linear mixed models were also used to 
estimate cholesterol means from 1994 to 2016 in strata 
according to LLD use. These models included indicator 
variables of survey number adjusted for birth cohort 
included as an ordinal variable with cubic polynomials 
(online supplementary material figure 2). An autoregres-
sive order 1 covariance matrix was specified to control 
for dependencies between repeated measures using 
restricted maximum likelihood as the estimation method. 
The first and the last author had full access to the data 
and take responsibility for its integrity and the data anal-
ysis. Statistical analyses were performed using SAS V.9.4.
results
Secular time trends
There was a secular decrease in mean cholesterol over 
six time points from 1979 to 2016 in both sexes and all 
age groups (table 1, figure 1). Although a more modest 
decrease or slight increase was observed between 1986 
and 1994, a significant linear decrease was observed in 
all age groups 30–89 years over the time period. For 
example, the decrease in mean cholesterol in age group 
40–49 years was 1.2 mmol/L in women and 1.0 mmol/L 
in men. Before the age of 50, women had lower mean 
cholesterol levels than men. The regression coefficients 
for those aged ≥30 years are presented in table 1, and 11 
out of 12 coefficients were not confounded, but HDL as 
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Table 3 Prevalence (%) of current lipid-lowering drugs use by sex, survey and age group: the Tromsø Study 1994–2016
Age group 
(years)
Tromsø 4 
1994–1995 
n=26 911
Tromsø 5 
2001 
n=8028
Tromsø 6 
2007–2008 
n=12 827
Tromsø 7 
2015–2016 
n=20 925 p Value*
Women
  20–29 0.1 – – – NA
  30–39 0.0 0.7 0.0 – 0.06
  40–49 0.2 0.8 1.5 1.8 <0.0001
  50–59 1.7 7.7 9.1 7.6 <0.0001
  60–69 3.3 13.6 17.6 20.0 <0.0001
  70–79 0.5 14.9 28.6 34.0 <0.0001
  80–89 0.0 12.2 23.0 33.4 <0.0001
Men
  20–29 0.1 – – – NA
  30–39 0.2 0.4 1.0 – 0.11
  40–49 1.1 2.8 4.0 4.5 <0.0001
  50–59 2.0 19.3 12.6 11.8 NA†
  60–69 2.8 17.9 24.1 25.1 <0.0001
  70–79 0.3 19.8 33.3 39.9 <0.0001
  80–89 0.0 9.0 32.5 40.6 <0.0001
*p Values are linear trend using GEE models.
†The GEE model did not converge for this age group and no test for linear trend is reported.
GEE, generalised estimating equation; NA, not applicable.
Figure 2 Population cholesterol distribution density curves (mmol/L) for Tromsø 4 1994–1995 overall (dashed lines) and for 
non-users of lipid-lowering drugs (LLD; dotted lines, embedded in the overall line due to few LLD users) and Tromsø 7 2015–
2016 overall (dash-dot lines) and for non-users of LLDs (solid lines), for women and men in age group 40–74 years. The Tromsø 
Study 1994–2016.
the regression coefficients changed by ≤8% when HDL 
was included in the model. Descriptive characteristics 
by survey is presented in online supplementary material 
table 1.
The 20th, 50th and 80th centiles of the mean choles-
terol distribution decreased between 1979 and 2016 in 
both sexes and all age groups (online supplementary 
material tables 2 and 3). The mean cholesterol decrease 
from 1994 to 2016 was somewhat higher in the 80th 
centile compared with the 20th centile (table 2), indi-
cating a possible treatment effect of high cholesterol 
levels. However, the cholesterol kernel density distribu-
tion curves (figure 2) indicate a shift to the left in the 
entire cholesterol distribution from 1994 to 2016 in both 
genders and all age groups, with a similar pattern for 
non-users of LLD.
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Figure 3 Observed longitudinal cholesterol (mmol/L) trends in women and men over surveys (1979–2016) (A and B) or age 
(20–89 years) (C and D) by 10-year birth cohorts (born 1910–1977) with 95% CIs. The Tromsø Study 1979–2016.
longitudinal trends
Longitudinal analysis included 43 565 subjects born 
between 1910 and 1977, by 10-year birth cohorts 
(figure 3). In most birth cohorts, mean total cholesterol 
increased with age and time until 1994 or 2001, followed 
by a decrease until 2016. In the youngest birth cohorts, 
the peak in total cholesterol was not yet observed by the 
end of follow-up in 2016. At any given age, total choles-
terol was significantly higher in older compared with 
younger birth cohorts. The different time trends between 
the birth cohorts have resulted in reduced variation in 
total cholesterol across birth cohorts from early in the 
observation period to the latest time points. The majority 
of the 95% CIs for the estimated marginal means in 
figure 3 are not overlapping, indicating significant differ-
ences between all birth cohorts at any given time point. In 
a separate set of analyses, we estimated linear trends from 
1994 to 2016 in each birth cohort and observed signifi-
cant decreasing trends for all birth cohorts except for the 
three youngest cohorts in women and the two youngest 
cohorts in men. Tests for interaction with time and birth 
cohort were highly significant (p values<0.0001), both in 
models where birth cohorts were included as indicator 
variables and as one ordinal variable, indicating that the 
decrease in total cholesterol became significantly steeper 
the older the birth cohort. The difference in time trends 
across birth cohorts became smaller when adjusted for 
LLD, but the interaction between time and cohort was 
still highly significant (p values<0.001 in both women 
and men). Analyses in a subsample of never-users of LLD 
showed similar trends as the total sample (online supple-
mentary material figure 1).
the use of lld treatment
Use of LLD was very rare in 1994 but increased between 
1994 and 2016 (table 3), especially in persons older than 
50 years. Among women and men younger than 50 years, 
use of LLD was less than 5% in all surveys. LLD was used 
more frequently by men than by women. Among those 
younger than 50 years, the estimated age-adjusted drop 
in mean cholesterol from 1994 to 2016 was 0.81 mmol/L 
in women and 0.82 mmol/L in men. Adjusted for LLD 
use, the decrease was 0.77 mmol/L and 0.72 mmol/L 
in women and men, respectively. Thus, among those 
younger than 50 years, the mean cholesterol decrease 
was not explained by LLD use. Among those aged 50 
years and older, the age-adjusted drop in mean choles-
terol from 1994 to 2016 was 1.22 mmol/L for women 
and 1.13 mmol/L for men. Adjusted for LLD use, the 
decrease was 0.97 mmol/L and 0.82 mmol/L in women 
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and men, respectively. Thus, among those 50 years and 
older, 21% of the decrease in women and 28% of the 
decrease in men was explained by treatment with LLD. 
Average total cholesterol level was lowered by about 
2.0 mmol/L among participants on LLD, and this effect 
was maintained on long-term therapy (online supple-
mentary material figure 2).
dIscussIOn
We found a substantial decrease in mean cholesterol 
levels in the general population between 1979 and 2016. 
Favourable trends were observed with age and time in 
women and men, in all age groups and in the oldest birth 
cohorts, and in both ends of the cholesterol distribution 
this shifted the distribution curve or cholesterol to the 
left. Subjects using LLD had a larger decrease in choles-
terol than non-users.
secular trends
The observed secular decrease in population cholesterol 
levels is similar to findings from cross-sectional popula-
tion-based surveys in other Nordic countries9 13 14 and 
the Czech MONICA and post-MONICA study,15 with 
Iceland showing the highest decline: 1.5 mmol/L among 
non-users of LLD aged 25–74 years during 1967–2008.13 
Studies from the USA of the same age groups and time 
period have shown a smaller decline: 0.5 mmol/L in 
National Health and Nutrition Examination Survey16 and 
0.3 mmol/L in the Minnesota Heart Survey.17
longitudinal trends
Previous population-based studies of longitudinal 
trends with repeated measurements were scarce and 
had limitations, studying one sex only,18–20 restricted age 
groups18 20–25 and/or have a very limited study period.18–27 
The lower mean cholesterol levels at any given age 
observed for younger compared with older birth cohorts 
can be related to both early life experience and exposures 
later in life, effects that are difficult to disentangle.28 The 
increase in cholesterol with age shifting to a decline in 
older age has previously been reported in several longi-
tudinal studies.18–20 25 27 In general, this can be a result of 
lifestyle changes, LLD use and survival bias. The unique 
contribution of age, period and cohort could not be 
isolated in our analyses. Previous studies have shown that 
adjustment for loss to follow-up17 27 did not influence the 
observed cholesterol decease with age. The participation 
rate in the Tromsø Study has fallen from an initial 79% to 
65% in the last survey, a decrease similar to reports from 
health examination surveys in various European coun-
tries.29 However, sensitivity analyses including Tromsø 
4 and Tromsø 6 participants showed that age-adjusted 
mean cholesterol did not differ between those who met to 
either and to both studies (online supplementary mate-
rial tables 4 and 5). This suggests that selection bias does 
not explain our findings.
the impact of lifestyle factors and lld treatment
Several cholesterol-associated lifestyle factors changed 
in the Tromsø Study population during the study period 
1979–2008. Mean body weight, body mass index and 
proportion of overweight and obese subjects increased 
in both genders and in every birth cohort and age 
group from 1974 to 199530 and further to 200831 in all 
groups of educational level.32 Occupational physical 
activity decreased, while the prevalence of moderate 
and vigorous physical activity in leisure time had a 
U-shaped trend between 1979 and 2008.33 Smoking 
prevalence decreased,34 while the frequency of alcohol 
consumption changed little.34 National trend data from 
consumer surveys and food supply statistics35 show that 
the overall composition of fatty acids in the diet has 
changed favourably from 1975 to 2000, including a steep 
decrease of transfat from 1990 to 2000 and thereafter 
stabilisation at the recommended level.35 However, after 
2000, the dietary intake of saturated fat has increased 
somewhat.35
Similar falls in the 80th, 50th and 20th percentile of 
the cholesterol distribution between 1994 and 2008 point 
to a population effect influenced by factors shifting the 
distribution curve to the left, rather than only a treat-
ment effect of individuals with hypercholesterolaemia. 
However, the 80th centile of the cholesterol distribution 
had a somewhat larger decrease than the 20th centile. 
LLD use did not explain the cholesterol decrease among 
those younger than 50 years, but LLD use had an effect on 
population cholesterol level among those aged 50 years 
and older. Patients on drug treatment would also have 
received lifestyle advice, and therefore observed choles-
terol changes among drug users will include the effect 
of lifestyle changes. In the US, LLD use was estimated 
to account for almost half of the small decrease in total 
cholesterol observed during the past two decades.16 This 
is in contrast with findings from Finland,36 Sweden14 and 
Iceland13 and the Czech Republic,15 where the effects of 
LLD use on population cholesterol levels were reported 
to be small.
Parallel trends in cVd
Analyses using the IMPACT mortality model on national 
registry data show that approximately 40% of the CHD 
mortality reduction can be explained by the decrease 
in total cholesterol in Norway’s neighbouring countries 
Finland5 and Sweden4 in the 15-year period from 1980 and 
onwards. A meta-analysis of 61 prospective observational 
studies mostly from Europe and the USA showed that a 
cholesterol decrease of 1.0 mmol/L was associated with 
a half, a third and a sixth lower ischaemic heart disease 
mortality in both genders at the ages of 40–49, 50–69 and 
70–89 years, respectively.37 In the Tromsø population, 
there has been a decline in CVD incidence38 39 in parallel 
with favourable trends in risk factor levels3 40 during the 
last three decades. Reduction in population cholesterol 
levels accounted for 32% of the decline in incidence of 
fatal and non-fatal CHD.3
8 Hopstock LA, et al. BMJ Open 2017;7:e015001. doi:10.1136/bmjopen-2016-015001
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strengths and weaknesses
The main strength of this study is the use of repeated 
measurements of total cholesterol and LLD use in the 
same individuals in a population-based sample, over a 
time period of four decades. The study sample size and 
recruitment from a general population increase general-
isability of the results. However, not all birth cohorts could 
be followed from young adulthood to older age, which 
can be observed in the figures of longitudinal trends. 
This can be explained by different sampling procedures 
between the surveys; not all former participants were 
reinvited to the following surveys. Only 59% of the study 
sample contributed with more than one measurement. 
Furthermore, another weakness is that data on poten-
tial mediators of cholesterol changes, such as weight and 
diet, were not included in the analyses. Ideally, the anal-
ysis should include all potential mediators, to investigate 
their impact on the trends.
cOnclusIOn
We found a substantial decrease in mean total cholesterol 
levels in the general population between 1979 and 2016 
in both sexes and all age groups. In birth cohorts, total 
cholesterol decreased after a peak around middle age, 
except for the youngest birth cohorts where a peak was 
not yet observed by the end of follow-up. The total choles-
terol distribution was shifted to the left in both ends of 
the curve. Subjects using LLD had a larger decrease in 
total cholesterol than non-users, but LLD use could only 
partly explain the population total cholesterol changes.
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